Workshop “Chikungunya vaccines- challenges, opportunities and possibilities”
The Department of Biotechnology, India (DBT) and Coalition for Epidemic Preparedness Innovations (CEPI) are organising a workshop “Chikungunya vaccines- challenges, opportunities and possibilities” on 5th and 6th February 2018 in Delhi, India. This workshop will bring together international delegates for two days of intense dialogue on ideas, data, challenges and opportunities related to Chikungunya vaccine development
To ensure we have good mix of participants and allow for vivid discussions, participation in the workshop is invitation only. All speakers and participants will be invited to the workshop in the next couple of weeks.
Invited speakers will lead a programme with oral presentations, lively panel discussions and stimulating poster sessions. A preliminary programme can be found below. In the agenda, we have reserved time for vaccine developers to present their vaccine candidates and would hereby like to invite those with a Chikungunya vaccine candidate to submit an abstract for selection for an oral presentation or poster (please see hyperlink for more information).
For more information related to this workshop, please contact firstname.lastname@example.org.
Request for abstracts
We would hereby like to invite everyone developing a vaccine for Chikungunya to submit an abstract for selection for an oral presentation or poster during the “Chikungunya vaccines- challenges, opportunities and possibilities" workshop in New Delhi on 5th and 6th February 2018.
Oral presentations will be part of Day 2 Session 4 “Vaccine candidates”. Posters or video will be presented during the entire workshop and during the reception on Day 1 there will be the opportunity to present and discuss the posters. All abstracts will be made accessible via CEPI website and used in a vaccine landscape overview, which we will present on Day 2 of the workshop.
Abstracts should present new research on Chikungunya vaccine development.
Abstract Title: Choose a title that reflects the main message of the presentation. Please spell pathogen names out in full. (Up to 85 characters, including space).
Affiliations and Authors: List all authors consecutively, separated by commas, with full first name and surnames. If authors have different affiliations, then number the affiliation(s) in superscript after each name. Write out each affiliation in full on a separate line with associated numbers.
Abstract text: Use the sections background, methods, results and conclusions. The text of this part of the abstract should not exceed 350 words (excluding title, authors, affiliations, and references). Where relevant include link to clinical trial registers and clinical trial results. Total abstract length (including Table/Figure and references) cannot exceed one page.
Table/Figure: Abstracts may also include one Table (max. 8 rows and 5 columns) OR one Figure.
References: Please use numbered references in both the text and the reference list. Maximum number of references is five.
Language: All abstracts must be submitted and presented in English.
Abbreviations: Please define all abbreviations when first used in the text.
Abstracts should be submitted in pdf format via the online registration portal or emailed to email@example.com by 1 pm CET on 24 November. After having submitted an abstract, confirmation is sent to the e-mail address given for the contact author provided in the system within 24 hours. Therefore, please make sure you have entered the correct email address in the submission system.
Abstract review and decision process
Abstracts are selected based on their scientific significance, time-lines, quality of data and methodology. The Scientific Program Committee will review and score submissions on these criteria and select abstract for oral presentations. Each author will receive a notification of acceptance or rejection by e-mail in the week of 18th December 2017. An accurate professional e-mail address for the presenting author is required for this purpose.